Safety/efficacy of MK-8669 (ridaforolimus) plus MK-2206 (AKT inhibitor) in patients with advanced breast cancer with low RAS signature and PTEN deficient prostate cancer.
暂无分享,去创建一个
P. Munster | S. Piha-Paul | A. Hollebecque | Jonathan D. Cheng | Shilpa Gupta | O. Dajani | A. Tosolini | G. Argilés | A. Swift